Regulatory FDA taps prior knowledge to expedite cell and gene therapy development BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Gene Therapy PlatformRead full story pharminent June 3, 2026 (Last updated: June 3, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie receives EC approval for Aquipta to treat migraineNext: Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
